Clinical Therapy Of Intravitreal Injection Of Triamcinolone Acetonide And Ranibizumab For Diabetic Macular Edema

Objective:To compare the vitreous injection of TA and Ranibizumab treatment the clinical curative effect of DME.Methods:Collected in January 2013-November 2014 in our hospital OCT and FFA examination, diagnosis of DME and used vitreous injection of TA and Ranibizumab treatment of 98 cases (98 eyes) of medical records were retrospectively analyzed.TA group of 49 cases (49 eyes), Ranibizumab group of 49 patients (49 eyes), compared two groups of postoperative 4 weeks,8 weeks,12 weeks of eye best corrected visual acuity, macular central retinal thickness (CMT), intraocular pressure and other complications.Results:statistical analysis:the general data of patients with preoperative patients with preoperative TA and Ranibizumab groups in age,sex,nationality, best corrected visual acuity,CMT,intraocular pressure,by comparison differences had no statistical significance (P>0.05).(1) vision:4 weeks,8 weeks,12 weeks postoperatively, TA and Ranibizumab groups postoperative each time compared with preoperative visual acuity improved obviously,the difference was statistically significant(P<0.05).Vitreous injection of TA and Ranibizumab postoperative eye eyesight to compare each time, there were no statistically significant difference (P>0.05).(2) the CMT:4 weeks,8 weeks,12 weeks postoperatively, TA and Ranibizumab groups each time after vitreous injection than preoperative were significantly reduced, the difference was statistically significant (P<0.05).(3) The intraocular pressure:4 weeks,8 weeks,12 weeks postoperatively,each time eye operation intraocular pressure after injection of TA group were significantly higher than Ranibizumab groups,differences were statistically significant(P<0.05), and TA groups had eyes each time after injection of eye were higher than preoperative lop difference was statistically significant(P<0.05), Ranibizumab groups of 4,8,12 weeks and there was no statistically significant difference than the preoperative intraocular pressure (P>0.05).Conclusion:Intravitreal injection of triamcinolone acetonide and ranibizumab in the treatment of diabetic macular edema(DME),can effectively control the condition of patients with DME,and can improve the patients’ vision,compare the efficacy of the two drugs showed vitreous cavity injection of triamcinolone acetonide for ranibizumab resistance is fast,but the safety of the ranibizumab treatment resistant is better,but still need further clinical test.